Document is current
Any future updates will be listed below
-
Authors
Wu, Yucai
Gong, Yanqing
Zhou, Liqun
Xu, Abai
Li, Xuesong
-
Funding
Funding for this research was provided by:
the National Key R&D Program of China (2023YFC2507001)
the National Natural Science Foundation of China (82273350)
the National Natural Science Foundation of China (82173216)
the Capital's Funds for Health Improvement and Research (2022-1-4072)
the Beijing Science and Technology Plan-Capital Clinical Diagnosis and Treatment Technology Research and Demonstration Application (Z211100002921070)
- License Information
-
More Information
Article History
Received: 18 August 2024
Revised: 16 January 2025
Accepted: 20 January 2025
First Online: 8 February 2025
Declarations
:
: This study was approved by the Medical Ethics Committee of Peking University First Hospital (Approval No.2020[307]), the Medical Ethics Committee of Zhujiang Hospital (Approval No.2021-SJ-029–02) and the Medical Ethics Committee of Meizhou People's Hospital (Approval No.2022-A-09). Participants signed an informed consent form prior to taking part. The clinical trial registration number is ChiCTR2200064162.
: The authors declare no potential competing interests.
